Table 5. Sensitivity Analyses: excluding bisphosphonates used to treat bone metastases; excluding prescriptions for bisphosphonates commenced 6 months or less before diagnosis of all UGI cancer; excluding cases where the READ code for UGI cancer diagnosis was uncertain.

UGI Cancer Odds Ratio (95% CI)
	Women	Men
Excluding bisphosphonates used to treat bone metastases, adjusted for smoking status	1.34 (1.14–1.57)	0.80 (0.61–1.05)
Excluding prescriptions for bisphosphonates commenced 6 months or less before diagnosis of all UGI cancer, adjusted for smoking status	1·30 (1·10–1·53)	0·77 (0·58–1·04)
Excluding cases where the READ code for UGI cancer diagnosis was uncertain, adjusted for smoking	1·34 (1·14–1·56)	0.81 (0·62–1·06)